Johnson & Johnson Alberta Health Innovation Partnership
Supporting innovation and advancement of patient and health system outcomes

In September of 2015, the University Hospital Foundation announced the Johnson & Johnson Alberta Health Innovation Partnership with the Government of Alberta – Economic Development and Trade (EDT) and Johnson & Johnson (J&J). 

This $2 million fund was established to support research & innovation in:

  • Prostate Cancer;
  • Diabetes;
  • Mental Health;
  • Microbiome;
  • Real World Evidence Projects;
  • and to connect Alberta’s Innovation Ecosystem to Global Markets.
ATIFPictured above: Edmonton Economic Development Corporation, City of Edmonton, Alberta Economic Development & Trade, and the University Hospital Foundation. 


In the first year the fund:

  • Distributed four grants of $75,000 through the launch of a prostate cancer research competition;
  • Provided $500,000 to support the development of the Alberta Health Incubator; and
  • Invested $165,000 in Real World Evidence research looking at The Use of Long Acting Injectable Antipsychotic Therapy for Schizophrenia through the Centre of Excellence in Real World Clinical Outcomes.

Through this investment in Real World Evidence, JAHIP is now internationally recognized by Johnson & Johnson as one of only five sites in the world participating in RWE, and awarded its first grant in RWE to the Centre for Excellence in Real World Clinical Outcomes.

On June 7, 2016, JAHIP awarded financial support to four Alberta-based prostate health research projects:

  • Biofluid Biomarkers to Distinguish Indolent from Aggressive Prostate Cancer
    • Principal Investigator: M. Eric Hyndman, University of Calgary
  • Prostate Proteases, Protease-Activated Receptors (PARs) & Prostate Cancer Progression
    • Principal Investigator: Morley D. Hollenberg, University of Calgary
  • Predicting Prostate Cancer Metastasis Using a Biofluid Diagnostic Approach
    • Principal Investigator: Dr. John Lewis, University of Alberta
  • Pilot Study of Changes in Androgen Receptor Splice Variant Status in Patients with Localized Prostate Cancer Undergoing Androgen Deprivation and Radiotherapy
    • Principal Investigator: Harvey Quon, University of Calgary

Download the press release: June 7, 2016 - Research Funding awarded to improve the treatment of Prostate Cancer

UHF Janssen


Donor Office - University of Alberta Hospital

1H1.91 WMC, 8440 – 112 Street NW, Edmonton, AB T6G 2B7

Donor Office - Mazankowski Alberta Heart Institute

2A9.006 MAHI, 8440 – 112 Street NW, Edmonton, AB T6G 2B7

Donor Office - Kaye Edmonton Clinic

1B.120 KEC, 11400 University Avenue, Edmonton, AB T6G 1Z1

University Hospital Foundation

Phone: 780-407-7007 | Fax: 780-407-6603
Charitable Registration Number  88900-3240 RR0001


AHP High Performer 2017    



Copyright 2018 University Hospital Foundation